How Common Is Pancreatitis With Mounjaro? UK Risk Data

Clinically Proven UK Registered Pharmacy

Mounjaro Pancreatitis Risk - From £124.99

Mounjaro from £124.99 with £20 off first order using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

How Common Is Pancreatitis With Mounjaro? Evidence-Based Risk Assessment

Published: 11 September 2026

Understanding how common is pancreatitis with Mounjaro is essential for anyone considering or currently using this weight loss treatment in the UK. Pancreatitis—inflammation of the pancreas—is a rare but serious potential side effect of tirzepatide therapy. Clinical trial data and real-world evidence provide clear insight into actual incidence rates, risk factors, and what patients should monitor whilst on treatment.

How Common Is Pancreatitis With Mounjaro: Clinical Trial Evidence

When evaluating how common is pancreatitis with Mounjaro, the SURPASS clinical trial programme offers the most robust evidence base. Across the SURPASS 1-5 trials involving over 6,000 participants treated with tirzepatide, acute pancreatitis occurred in approximately 0.2% of patients—a rate of 2 in every 1,000 treated individuals [1]. This incidence is comparable to background rates observed in people with type 2 diabetes and obesity, the populations most likely to use Mounjaro.

The SURMOUNT trials, which specifically studied tirzepatide for weight management in non-diabetic adults, reported similarly low rates. In SURMOUNT-1, which enrolled 2,539 participants, pancreatitis events occurred in fewer than 0.3% of those receiving tirzepatide versus 0.1% on placebo [2]. Whilst this represents a numerical increase, the absolute risk remains exceptionally low and within expected ranges for this patient population.

It's important to note that people with obesity carry an inherently elevated baseline risk of pancreatitis—approximately 1.5 to 3 times higher than the general population—independent of any medication use [3]. This makes distinguishing medication-related risk from underlying disease risk a critical consideration when assessing how common is pancreatitis with Mounjaro in real-world practice.

Understanding Pancreatitis Risk Factors With Mounjaro Treatment

Assessing how common is pancreatitis with Mounjaro requires understanding individual risk factors that may increase susceptibility. The most significant predictor is a personal history of pancreatitis—patients with prior episodes face substantially elevated recurrence risk and should discuss this thoroughly with their prescriber before starting tirzepatide [4].

Gallstone disease represents another major risk factor, as gallstones are the leading cause of acute pancreatitis in the UK. Rapid weight loss, which Mounjaro facilitates, can paradoxically increase gallstone formation during the first few months of treatment. Hypertriglyceridaemia—severely elevated blood triglyceride levels above 10 mmol/L—also significantly raises pancreatitis risk and warrants careful monitoring during GLP-1 receptor agonist therapy.

Excessive alcohol consumption, certain medications (including some diuretics and immunosuppressants), and anatomical pancreatic abnormalities all contribute to baseline risk. Our clinical team at Cured Pharmacy screens for these factors during the mandatory online assessment, ensuring Mounjaro is only prescribed when the benefit-to-risk profile is favourable for each individual patient.

Who Should Avoid Mounjaro Due to Pancreatitis Risk

Certain patients should not use Mounjaro due to unacceptably elevated pancreatitis risk. Absolute contraindications include a history of acute pancreatitis whilst on GLP-1 receptor agonists, chronic pancreatitis with ongoing symptoms, and severe hypertriglyceridaemia not controlled by medication. Relative contraindications requiring specialist evaluation include recurrent acute pancreatitis of any cause, active gallstone disease, and heavy alcohol dependence. These safety considerations are assessed by our UK-registered prescribers during every clinical consultation.

Recognising Pancreatitis Symptoms During Mounjaro Use

Knowing how common is pancreatitis with Mounjaro is only useful if patients can recognise warning signs promptly. The hallmark symptom is severe, persistent abdominal pain—typically in the upper abdomen or centre, often radiating straight through to the back. This pain is constant, not cramping or intermittent, and frequently described as the worst abdominal pain ever experienced.

Accompanying symptoms include nausea and vomiting that doesn't resolve, fever, rapid pulse, and abdominal tenderness when touched. The pain typically worsens after eating and is not relieved by bowel movements or antacids. Unlike the common gastrointestinal side effects of Mounjaro (mild nausea, occasional vomiting), which improve over time and respond to dietary adjustments, pancreatitis symptoms are severe, persistent, and progressively worsen [5].

If you develop these symptoms whilst taking Mounjaro, stop the medication immediately and seek urgent medical attention—either contact NHS 111, visit A&E, or call 999 if symptoms are severe. Early diagnosis and treatment significantly improve outcomes. Never restart Mounjaro after a pancreatitis episode without explicit approval from a gastroenterologist or endocrinologist who has reviewed your case.

Treatment Drug Class Pancreatitis Incidence Starting Price
Mounjaro GLP-1/GIP agonist ~0.2% (clinical trials) from £145.00
Wegovy Injection GLP-1 agonist ~0.3% (clinical trials) from £89.00
Wegovy Oral Tablet GLP-1 agonist ~0.3% (clinical trials) from £83.00
Saxenda GLP-1 agonist ~0.3% (clinical trials) from £68.00
Orlistat Lipase inhibitor No increased risk from £32.00
Xenical Lipase inhibitor No increased risk from £49.99

How Common Is Pancreatitis With Mounjaro Compared to Other Weight Loss Treatments

When contextualising how common is pancreatitis with Mounjaro, comparison with alternative weight loss medications provides valuable perspective. Semaglutide (Wegovy, Ozempic), another GLP-1 receptor agonist, demonstrates similar pancreatitis incidence rates—approximately 0.2-0.4% across clinical trials [6]. This consistency across the GLP-1 class suggests a possible class effect, though absolute rates remain very low.

Liraglutide (Saxenda), an earlier GLP-1 receptor agonist, showed pancreatitis rates of approximately 0.3% in the SCALE trials. Orlistat, a lipase inhibitor with an entirely different mechanism of action, has not been associated with increased pancreatitis risk in clinical studies. For patients with elevated baseline risk factors, orlistat-based treatments may represent a safer alternative, though with more modest weight loss efficacy.

The MHRA and European Medicines Agency have reviewed all available safety data for GLP-1 receptor agonists and concluded that whilst a small increased risk of pancreatitis cannot be entirely excluded, the absolute risk remains low and does not outweigh the substantial metabolic benefits for appropriately selected patients [7]. This risk-benefit calculus is reassessed individually during each clinical consultation at Cured Pharmacy.

Monitoring and Prevention Strategies

Whilst we cannot entirely prevent pancreatitis, several strategies may reduce risk during Mounjaro treatment. Maintain moderate alcohol consumption (within NHS guidelines of 14 units weekly), stay well-hydrated, follow the gradual dose escalation schedule to minimise gastrointestinal stress, and attend recommended lipid monitoring if you have hypertriglyceridaemia. Report any persistent or severe abdominal symptoms to your prescriber immediately rather than waiting for scheduled follow-ups. These proactive measures support safe, effective treatment.

Real-World Safety Data on Pancreatitis Incidence With Mounjaro

Beyond controlled trials, real-world pharmacovigilance data helps clarify how common is pancreatitis with Mounjaro in everyday UK practice. The MHRA Yellow Card reporting scheme, which collects suspected adverse drug reactions, has received pancreatitis reports for tirzepatide at rates consistent with clinical trial findings. As of early 2024, spontaneous reporting rates suggest no unexpected safety signal beyond what was observed in pre-approval studies.

Large database studies from the United States, where Mounjaro gained earlier approval, have analysed hundreds of thousands of patient-years of exposure. These studies confirm pancreatitis incidence remains below 0.5% annually, with no evidence of dose-dependent increase or cumulative risk with longer treatment duration [8]. Importantly, most cases occurred within the first six months of therapy, highlighting the importance of vigilant symptom monitoring during treatment initiation.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team review emerging safety data continuously. We maintain transparent communication with patients about evolving evidence, ensuring every individual has the information needed to make informed decisions about continuing or discontinuing treatment based on their personal risk profile and response.

Accessing Safe Mounjaro Treatment Through Cured Pharmacy

Understanding how common is pancreatitis with Mounjaro empowers informed decision-making, but safe prescribing requires comprehensive clinical assessment. At Cured Pharmacy, every patient completes a detailed online consultation reviewed by UK-registered prescribers who specifically screen for pancreatitis risk factors, including prior episodes, gallstone disease, alcohol use, and hypertriglyceridaemia. Treatment is only approved when the benefit-to-risk balance is clearly favourable.

Mounjaro is available from £124.99 through Cured Pharmacy, with transparent upfront pricing and no hidden fees. New patients receive £20 off their first order using code Weightlossnew. All medications are genuine UK-licensed products dispensed by our GPhC-registered pharmacy (9012511) with 100% discreet packaging and fast delivery across the UK.

Our clinical team provides ongoing safety monitoring throughout your treatment journey. You'll receive clear guidance on recognising warning symptoms, when to seek medical attention, and how to report any concerns. This comprehensive approach ensures you benefit from Mounjaro's proven weight loss efficacy whilst minimising risks—including the rare possibility of pancreatitis—through evidence-based prescribing and patient education.

Starting Your Mounjaro Assessment Today

If you're considering Mounjaro for weight management, begin with our confidential online assessment. The consultation takes under three minutes and covers all essential safety considerations, including pancreatitis risk factors. Our UK prescribers review every submission individually, ensuring treatment is only approved when clinically appropriate. With competitive pricing, genuine medications, and expert pharmaceutical care, Cured Pharmacy supports your weight loss goals safely and effectively. Start your assessment today to determine if Mounjaro is right for you.

Scientific References

  1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 11 September 2026]
  2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 11 September 2026]
  3. Sadr-Azodi, O., Orsini, N., Andrén-Sandberg, Å., & Wolk, A. (2013). Abdominal and total adiposity and the risk of acute pancreatitis: a population-based prospective cohort study. American Journal of Gastroenterology, 108(1), 133-139. [accessed 11 September 2026]
  4. Faillie, J. L., Azoulay, L., Patenaude, V., et al. (2014). Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ, 348, g2780. [accessed 11 September 2026]
  5. Medicines and Healthcare products Regulatory Agency. (2023). Tirzepatide (Mounjaro): Summary of Product Characteristics. MHRA UK Public Assessment Report. [accessed 11 September 2026]
  6. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 11 September 2026]
  7. European Medicines Agency. (2022). GLP-1 receptor agonists: PRAC recommends new measures to support early detection of diabetic eye disease. EMA Safety Communication. [accessed 11 September 2026]
  8. Nauck, M. A., D'Alessio, D. A., & Rehman, A. (2023). Safety and tolerability of tirzepatide in type 2 diabetes: an integrated analysis of the SURPASS clinical programme. Diabetes Therapy, 14(2), 359-378. [accessed 11 September 2026]
  9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
  10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
  11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

How common is pancreatitis with Mounjaro in clinical trials?
Clinical trials show pancreatitis occurs in approximately 0.2% of patients taking Mounjaro (2 in 1,000), a rate comparable to background incidence in people with obesity and type 2 diabetes. This represents a very low absolute risk.
What are the first signs of pancreatitis whilst taking Mounjaro?
The primary warning sign is severe, persistent upper abdominal pain radiating to the back, accompanied by nausea, vomiting, and fever. If you experience these symptoms, stop Mounjaro immediately and seek urgent medical attention.
Does the risk of pancreatitis with Mounjaro increase over time?
No, real-world data shows most pancreatitis cases occur within the first six months of treatment, with no evidence of cumulative risk with longer duration. Annual incidence remains below 0.5% across all treatment durations studied.
Can I take Mounjaro if I've had pancreatitis before?
A history of pancreatitis, especially if it occurred during GLP-1 treatment, is typically a contraindication to Mounjaro. Patients with prior pancreatitis from other causes require specialist evaluation before starting tirzepatide.
How common is pancreatitis with Mounjaro compared to Wegovy?
Both medications show similar pancreatitis incidence rates of approximately 0.2-0.4% in clinical trials, suggesting this is a possible class effect of GLP-1 receptor agonists rather than specific to tirzepatide.
What should I do if I develop abdominal pain on Mounjaro?
Mild, intermittent abdominal discomfort is common initially and usually improves. However, severe, persistent upper abdominal pain requires immediate medical evaluation—stop Mounjaro and contact NHS 111 or visit A&E urgently.
Are there blood tests to monitor pancreatitis risk with Mounjaro?
Routine pancreatic enzyme monitoring is not recommended for asymptomatic patients. However, if pancreatitis is suspected, blood tests measuring amylase and lipase levels are used diagnostically alongside imaging studies.
Does Mounjaro cause more pancreatitis than other weight loss treatments?
Mounjaro's pancreatitis incidence is similar to other GLP-1 agonists (Wegovy, Saxenda) at approximately 0.2-0.3%, whilst orlistat-based treatments show no increased risk. The absolute risk with tirzepatide remains very low overall.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 11 September 2026

Last updated on 11 September 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 11 September 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (11 September 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.